Sign in

ALLR on Nasdaq

Allarity Therapeutics, Inc.

American pharmaceutical preparations company based in Boston1

In its 2026 annual report the company says: “We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We have developed and published DRP® signatures for dozens of anti-cancer therapeutics.”4 Its shares trade on Nasdaq under the symbol ALLR.1

$0.84 down 0.03 (3.79%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 21, 2026.

Overview

Compare with Vyome Holdings, Inc, Immuneering Corp or Edesa Biotech, Inc., or pick any stock.

  • TickerALLR on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersBoston, Massachusetts1
  • Incorporated inDE3
  • Business address24 School St., 2Nd Floor, Boston, Ma 021083
  • Filer category, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation of our novel Drug Response Predictor (DRP®) platform. The DRP® technology is designed to define the gene expression signatures in cancer cells that predict the cancer cell’s sensitivity to a specific cancer therapeutic. Once defined, the DRP® gene expression signature can then be assessed in cancer tissue biopsies from patients to identify those cancers that share this signature of drug sensitivity, and by extension, to identify those patients who may then be most likely to receive benefit from that specific anti-cancer therapeutic. We have developed and published DRP® signatures for dozens of anti-cancer therapeutics. Ideally, by using DRP to identify the patients most likely to benefit clinic…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-3939.1%Operating margin5
-3509.7%Net margin5
-114.3%Return on equity5
-$14.8MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$6.6M

Out of $320.0K in revenue.5 The company lost money this year.

Financial statements

Revenue5$320.0K in 2025
0$100.0K$200.0K$300.0K$400.0K2024: $0$020242025: $320.0K$320.0K2025
Operating income78695-$12.6M in 2025+52% since 2020
-$40.0M-$30.0M-$20.0M-$10.0M02020: -$8.3M-$8.3M20202021: -$26.6M-$26.6M2021+219%2022: -$34.5M-$34.5M2022+30%2023: -$17.1M-$17.1M2023−50%2024: -$27.2M-$27.2M2024+59%2025: -$12.6M-$12.6M2025−54%
Net income78695-$11.2M in 2025+70% since 2020
-$30.0M-$20.0M-$10.0M02020: -$6.6M-$6.6M20202021: -$26.6M-$26.6M2021+303%2022: -$16.1M-$16.1M2022−40%2023: -$11.9M-$11.9M2023−26%2024: -$24.5M-$24.5M2024+106%2025: -$11.2M-$11.2M2025−54%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue$320.0K$0
Research and development$6.6M$6.1M
Impairment of intangible assets$0$9.7M
General and administrative$6.3M$11.4M
Total operating expenses$12.9M$27.2M
Loss from operations-$12.6M-$27.2M
Interest income$801.0K$533.0K
Interest expenses-$185.0K-$653.0K
Foreign exchange gains (losses)$757.0K-$212.0K
Change in fair value adjustment of warrant derivative liabilities$1.0K$2.7M
Total other income$1.4M$2.3M
Loss before income tax expense (benefit)-$11.2M-$24.9M
Income tax expense (benefit)$0-$381.0K
Net loss-$11.2M-$24.5M
Net loss attributable to common stockholders-$11.2M-$25.2M
Net loss per common share, basic and diluted (in dollars per share)-$0.78-$15.65
Weighted average common shares outstanding, basic and diluted (in shares)14.4M shares1.6M shares
Change in cumulative translation adjustment-$667.0K$57.0K
Total comprehensive loss-$11.9M-$24.5M

Compare Allarity Therapeutics, Inc. with another company

Corporate structure

Allarity Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Allarity Therapeutics, Inc.

  • 3i, LP Filed SC 13G/A on Allarity Therapeutics, Inc., latest Nov 13, 2024 (3 filings since Mar 2, 2023)
  • Olmsted Investments LLC Filed SCHEDULE 13G on Allarity Therapeutics, Inc., latest Aug 29, 2024
  • Streeterville Capital LLC Filed SC 13G on Allarity Therapeutics, Inc., latest Aug 29, 2024
  • INTRACOASTAL CAPITAL, LLC Filed SC 13G on Allarity Therapeutics, Inc., latest Jul 14, 2023 (2 filings since Apr 28, 2023)
  • Forsakringsaktiebolaget Avanza Pension Filed SC 13G/A on Allarity Therapeutics, Inc., latest Mar 10, 2023 (6 filings since Dec 27, 2021)
  • &. Larsen Aps Sass Filed SC 13G on Allarity Therapeutics, Inc., latest Dec 22, 2021
  • Allarity Therapeutics, Inc. Boston, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Allarity Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$330.0K5 Dec 31, 2025$309.0K5 Dec 31, 2024+6.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$14.7M5 Dec 31, 2025$19.5M5 Dec 31, 2024−24.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$09 Dec 31, 2024$9.9M9 Dec 31, 2023−100.0%

Properties, in its own words

Our principal executive office is located at 123 E. Tarpon Ave., Tarpon Springs, FL 34689. We lease at-will, month-to-month the virtual office space, where we are not bound by any lease. Additionally, we lease a space in a technology park consisting of approximately 4,283 square feet in Hoersholm, Denmark. The facility lease in continuing on a month-to-month basis. We believe that our facilities are adequate to meet our current needs and the additional space can be obtained on commercially reasonable terms as needed.

Item 2 of the 10-K filed Mar 30, 2026.4

Leadership

Who has led Allarity Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steve Carchedi2021

Chief financial officer

  1. Jens Erik Knudsen2021–2022
  2. Joan Yvonne Brown2022
  3. Alexander Epshinsky2024–2025
  4. Jeffrey S. Ervin2025–now
2025
Board members and other officers (13)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorThomas Jensen named Mar 1, 2023 to Feb 2, 202429

Timeline

  1. Oct 1, 20268-K Other events30
  2. Sep 29, 20268-K Other events31
  3. Sep 16, 20268-K Other events32
  4. Sep 14, 20268-K Other events33
  5. Aug 14, 20268-K Results of operations34
  6. Jul 1, 20268-K Shareholder vote; Other events35
  7. Jun 22, 20268-K Other events36
  8. Jun 2, 20268-K Executive or director change37
  9. May 8, 20268-K Regulation FD disclosure; Other events38
  10. May 6, 20268-K Other events39
  11. Apr 28, 20268-K Other events40
  12. Apr 22, 20268-K Other events41
  13. Dec 22, 2021New chief executive Steve Carchedi becomes CEO12

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.19) a share, on Nov 14, 2025.42

When it reported results

  1. Aug 14, 2026Reported quarterly or annual results34
  2. Apr 1, 2026Reported quarterly or annual results43
  3. May 9, 2025Reported quarterly or annual results44
  4. Mar 31, 2025Reported quarterly or annual results45
  5. Nov 14, 2024Reported quarterly or annual results46
  6. May 24, 2024Reported quarterly or annual results47
  7. May 15, 2024Reported quarterly or annual results48
  8. Mar 8, 2024Reported quarterly or annual results49

Drug trials and FDA: coming up

  1. Mar 2027Phase 2 trial readout expected Phase 2 trial of 2X-121 in Advanced Ovarian Cancer: primary completion expected Mar 2027 (ClinicalTrials.gov NCT03878849).50

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

384 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 158 major events, 38 insider forms, 14 large holders, 5 private raises, 147 other. The latest 20:

  1. Oct 9, 20264 EDGAR
  2. Oct 1, 20268-K CURRENT REPORT EDGAR
  3. Sep 29, 20268-K CURRENT REPORT EDGAR
  4. Sep 16, 20268-K CURRENT REPORT EDGAR
  5. Sep 14, 20268-K CURRENT REPORT EDGAR
  6. Aug 14, 202610-Q EDGAR
  7. Aug 14, 20268-K CURRENT REPORT EDGAR
  8. Jul 1, 20268-K CURRENT REPORT EDGAR
  9. Jun 22, 20268-K CURRENT REPORT EDGAR
  10. Jun 2, 20268-K CURRENT REPORT EDGAR
  11. May 15, 202610-Q EDGAR
  12. May 14, 20264 OWNERSHIP DOCUMENT EDGAR
  13. May 11, 20264 OWNERSHIP DOCUMENT EDGAR
  14. May 11, 20263 EDGAR
  15. May 8, 20268-K CURRENT REPORT EDGAR
  16. May 7, 20264 OWNERSHIP DOCUMENT EDGAR
  17. May 6, 20268-K CURRENT REPORT EDGAR
  18. Apr 30, 2026ARS ANNUAL REPORT EDGAR
  19. Apr 30, 2026DEFA14A PROXY STATEMENT EDGAR
  20. Apr 30, 2026DEF 14A PROXY STATEMENT EDGAR

The 384 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Thomas H. Jensen47$647.4K$1.5M57
2025Jeremy R. Graff56$494.0K$908.8K57
2025Alexander Epshinsky$176.8K$383.5K57
2025Steen Knudsen65$168.3K$236.8K57
2025Jeffrey S. Ervin48$119.6K$158.5K57
2024Chief Executive Officer$507.9K$791.6K57
2024President and Chief Development Officer$120.5K$519.2K57
2024Former Chief Financial Officer$102.0K$349.4K57
2024Chief Scientific Officer$140.9K$197.3K57

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$6.9M 2022–2024
Money received by yearMoney received by year, 2022–2024: $6.9M in all. Private raises (Form D) $6.9M.$0$1M$2M$3M$4M2022 · Private raises (Form D): $3.4M20222023 · Private raises (Form D): $3.2M20232024 · Private raises (Form D): $400.0K2024
Figures by year
YearPrivate raises (Form D)Total
2024$400.0K$400.0K
2023$3.2M$3.2M
2022$3.4M$3.4M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jan 18, 2024Raised $400,000 in a private offering of debt29 Form D: $1.4 million offered in all Form D
  2. Sep 18, 2023Raised $1.6 million in a private offering of equity58 Form D: 2 investors so far Form D
  3. Apr 21, 2023Raised $350,000 in a private offering of equity59 Form D: 1 investor so far Form D
  4. Feb 28, 2023Raised $1.2 million in a private offering of equity60 Form D: 1 investor so far Form D
  5. Nov 28, 2022Raised $3.4 million in a private offering of debt61 Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Renaissance Technologies LLC331,509$427.6K0.0%+103,425
Vanguard Capital Management LLC171,795$221.6K0.0%No change
Geode Capital Management, LLC154,867$199.8K0.0%−35,526
State Street Corp137,600$177.5K0.0%No change
Militia Capital Management LLC98,978$127.7K0.0%New
Citadel Advisors LLC91,748$118.4K0.0%New
Vanguard Fiduciary Trust Co74,913$96.6K0.0%No change
Northern Trust Corp36,534$47.1K0.0%−11,569
Jane Street Group, LLC36,021$46.5K0.0%New
Two Sigma Investments, LP27,492$35.5K0.0%No change
UBS Group AG26,589$34.3K0.0%+3,431
XTX Topco Ltd20,884$26.9K0.0%−8,083
Susquehanna International Group, Llp17,221$22.2K0.0%New
Tower Research Capital LLC (TRC)2,650$3.4K0.0%New
Hrt Financial LP37,003$470.0%New
Caitong International Asset Management Co., Ltd22$280.0%+21
Virtu Financial LLC15,322$200.0%New
Fmr LLC13$170.0%New
Danske Bank A/s1$10.0%No change
Jones Financial Companies Lllp1$10.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Allarity Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAllarity Therapeutics, Inc.1
  • CIK0001860657
  • Employer ID (EIN)87-21479824
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address24 School St., 2Nd Floor, Boston, MA 021081
  • Phone401-426-46641
  • Shares outstanding15,910,724 as of Aug 14, 202611
  • Public float$14.7M as of Jun 30, 20254
  • AuditorWolf & Company P.C., Boston, Massachusetts PCAOB ID 392; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMay 27, 20211
  • Filings400 in all: 8-K (153), 424B3 (22), 3 (19), CORRESP (16), 10-Q (15), 4 (15), 424B5 (14), S-1/A (13)1
    All 41 form types

    425 (11), EFFECT (11), UPLOAD (11), DEFA14A (9), DEF 14A (8), PRE 14A (7), S-4/A (7), SC 13G/A (7), D (6), S-3 (6), SC 13G (6), 10-K (5), 8-K/A (5), 4/A (4), S-1 (4), ARS (3), NT 10-Q (3), 424B4 (2), RW (2), S-3/A (2), SEC STAFF LETTER (2), 10-K/A (1), 10-Q/A (1), 8-A12B (1), CERT (1), DEFR14A (1), DRS (1), NT 10-K (1), POS AM (1), PRER14A (1), S-4 (1), S-8 (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Apr 30, 2026
    Latest 8-K (8-K) Oct 1, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareALLRNasdaq

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Allarity Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 72 risks under these headings, as written.4

  • Risks Related to Our Business and Industry
  • We may become delinquent in our payments to Eisai. In consideration for extension of certain deadlines and payment obligations, we entered into several amendments to an Exclusive License Agreement with Eisai.
  • Unstable global market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.
  • If we fail to satisfy the Nasdaq Capital Market continued listing requirements and do not regain compliance, our common stock will be delisted.
  • We will need to increase the size of our organization and the scope of our outside vendor relationships, and we may experience difficulties in managing growth.
  • We depend on our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.
  • Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
  • International operations may expose us to business, regulatory, political, operational, financial, pricing, tariffs, and reimbursement risks associated with doing business outside of the U.S.
  • Our failure to successfully acquire, develop, and market additional therapeutic candidates could impair our ability to grow.
  • We have obtained statistical data, market data and other industry data and forecasts used throughout this Annual Report from market research, publicly available information and industry publications which we believe are reliable.
  • Risks Related to Our Financial Position and Need for Additional Capital
  • We have a limited operating history with no product revenues to date and a limited number of DRP® biomarker development agreements, which may make it difficult to evaluate the success of our business to date and to assess our future viability.
The other 62 risks
  • We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.
  • We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our drug development program for stenoparib or its commercialization efforts.
  • Failure to achieve and maintain effective internal controls could have a material adverse effect on our business.
  • Risks Related to the Discovery and Development of Stenoparib
  • Clinical trials are very expensive, time-consuming and difficult to design and implement, and involve uncertain outcomes. Furthermore, results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical trials.
  • We may encounter substantial delays in our preclinical studies or clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.
  • If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • If we fail to comply with our obligations in the agreements under which we have licensed the intellectual property rights from third parties for stenoparib or otherwise experience disruptions to our business relationships with our licensors, we could lose rights to advance the development of stenoparib which would have a material adverse effect on our business.
  • We may expend our limited resources to pursue a particular therapeutic candidate or indication and fail to capitalize on therapeutic candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • We have limited experience in drug discovery and drug development and may not receive regulatory approval to market stenoparib.
  • Our business strategy of using our proprietary DRP® companion diagnostics platform to advance stenoparib may not be successful, and important issues relating to safety and efficacy remain to be resolved for stenoparib. Our strategy also involves risks and uncertainties that differ from other biotechnology companies that focus solely on new therapeutic candidates.
  • Smerud Medical Research International and Chosa ApS are responsible for the development of our LiPlaCis® in conjunction with our DRP® companion diagnostic.
  • We may depend on enrollment of patients with specific genomic or biomarker signatures, identified through DRP® companion diagnostics, in our clinical trials in order for us to continue development of stenoparib. If we are unable to enroll patients with specific genomic or biomarker signatures in our clinical trials, our research, development and commercialization efforts could be adversely affected.
  • Delays in clinical testing could result in increased costs to us and delay our ability to generate revenue.
  • Stenoparib may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
  • Our proprietary DRP® companion diagnostics platform may fail to help us select and treat likely responder patients for stenoparib or help us identify additional potential therapeutic candidates.
  • Any failure by us to comply with existing regulations could harm our reputation and operating results.
  • We may be subject to extensive regulations outside the U.S. and may not obtain marketing approvals for stenoparib in Europe and other jurisdictions.
  • Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors and customers will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
  • Our inability to obtain or retain sufficient clinical trial liability insurance at an acceptable cost to protect against potential liability claims could prevent or inhibit our ability to conduct clinical trials for stenoparib.
  • Risks Related to the Approval and Commercialization of Stenoparib
  • Even if we are successful in completing all preclinical studies and clinical trials, we may not be successful in commercializing stenoparib.
  • If our drugs do not gain market acceptance, our business will suffer because we might not be able to fund future operations.
  • We may in the future develop therapeutic candidates in combination with other therapies and that may expose us to additional risks.
  • We may rely on orphan drug status to commercialize stenoparib, and even if orphan drug status is approved, such approval may not confer marketing exclusivity or other commercial advantages or expected commercial benefits.
  • A Breakthrough Therapy designation by the FDA for stenoparib may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that stenoparib will receive marketing approval.
  • A Fast Track designation by the FDA may not lead to a faster development or regulatory review or approval process.
  • Failure to obtain marketing approval in foreign jurisdictions would prevent stenoparib from being marketed abroad.
  • If we are required by the FDA to obtain approval of a DRP® companion diagnostic in connection with approval of stenoparib, and we do not obtain or face delays in obtaining FDA approval of a DRP® diagnostic device, we will not be able to commercialize stenoparib and our ability to generate revenue will be materially impaired.
  • Any therapeutic candidate for which we obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements, improperly promoted off-market label uses of our drugs or therapeutic candidates or if we experience unanticipated problems with our drugs, when and if any of them are approved.
  • We operate in a highly competitive and rapidly changing industry.
  • If we are unable to develop satisfactory sales and marketing capabilities, we may not succeed in commercializing stenoparib.
  • Even if we obtain regulatory approvals to commercialize stenoparib, stenoparib may not be accepted by physicians or the medical community in general.
  • Healthcare reform measures could hinder or prevent stenoparib's commercial success.
  • Governmental efforts to pursue regulatory reform may limit the FDA’s ability to engage in oversight and implementation activities in the normal course, and that could negatively impact our business.
  • Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize stenoparib and may affect the price we may set.
  • Governments outside of the U.S. tend to impose strict price controls, which may adversely affect our revenues, if any.
  • If we or any third-party manufacturers or contractors we engage now or in the future fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could harm our business.
  • We may experience challenges with the acquisition, development, enhancement or deployment of technology necessary for our proprietary DRP® companion diagnostics platform.
  • Risks Related to Our Reliance on Third Parties
  • We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully perform their contractual legal and regulatory duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize stenoparib and our business could be substantially harmed.
  • We, or third-party manufacturers on whom we rely, may be unable to successfully scale-up manufacturing of stenoparib in sufficient quality and quantity, which would delay or prevent us from developing and commercializing stenoparib.
  • Our failure to find third-party collaborators to assist or share in the costs of drug development could materially harm our business, financial condition and results of operations.
  • Risks Related to Our Intellectual Property
  • If we do not obtain patent term extension for stenoparib or obtain a patent on our DRP® companion diagnostic for stenoparib, our business may be materially harmed.
  • Changes to patent laws in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect stenoparib.
  • We or our licensors may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.
  • Third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
  • Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
  • Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to our business.
  • We may not be able to protect our intellectual property and proprietary rights throughout the world.
  • We may be subject to claims by third parties asserting that our employees, consultants, contractors or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their trade secret or claiming ownership of what we regard as our own intellectual property.
  • Intellectual property rights do not necessarily address all potential threats.
  • Risks Related to Ownership of our Securities and Our Status as a Public Company
  • If our business developments and achievements do not meet the expectations of investors or securities analysts or for other reasons the expected benefits do not occur, the market price of our common stock traded on Nasdaq may decline.
  • The price of our common stock has fluctuated substantially.
  • Future sales, or the perception of future sales, by us or our stockholders in the public market could cause the market price for our common stock to decline.
  • Because there are no current plans to pay cash dividends on shares of our common stock for the foreseeable future, you may not receive any return on investment unless you sell your shares of common stock for a price greater than that which you paid for it.
  • There is no assurance that an active and liquid trading market in our common stock will develop.
  • Our Certificate of Incorporation and our by-laws, and Delaware law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline.
  • Our Certificate of Incorporation designates the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) as the exclusive forum for certain types of claims that the federal courts do not have exclusive jurisdiction, which may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable.
  • General Risk Factors
  • We are an “emerging growth company” and a “smaller reporting company” and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make our common stock less attractive to investors.
  • We may be at risk of securities class action litigation.
  • Financial reporting obligations of being a public company in the U.S. require well defined disclosure and procedures and internal control over financial reporting that that are expensive and time-consuming requiring our management to devote substantial time to compliance matters.
  • We may acquire other companies or technologies, which could divert our management’s attention, result in dilution to our stockholders and otherwise disrupt our operations and adversely affect our operating results.
  • Market and economic conditions may negatively impact our business, financial condition and share price.

Legal proceedings

For information regarding our material legal proceedings, see “Note 14. Commitments and Contingencies” in the accompanying “Notes to Consolidated Financial Statements” in this Annual Report, which information is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
    Yahoo FinanceALLR quote
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
    SEC EDGAROther events
  32. 32
    SEC EDGAROther events
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
    SEC EDGAROther events
  41. 41
    SEC EDGAROther events
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61